A biosimilar is a biologic product that is highly similar to another approved biologic product, known as “reference product”, and has no clinically meaningful differences in terms of effectiveness, safety or exposure from the reference product.
We bring years of pharmaceutical development experience to offer high-quality biosimilars to patients
In line with our corporate philosophy of “caring for life”, we have entered into the biosimilars area, as a part of our passion and commitment to unlocking access to life-saving medicines for more patients.
Well positioned to achieve this goal, Fresenius Kabi is equipped with extensive experience in the manufacture and supply of injectables and complex formulations, as well as global expertise in the development of biologics.
In the areas of oncology and immunology. Fresenius Kabi applies the same high-quality standards in developing and producing biosimilars as is required for the reference product.
Fresenius Kabi Biosimilars in Immunology and Oncology
Providing affordable and high-quality healthcare to patients coping with chronic diseases is an integral part of Fresenius Kabi’s purpose, and this is demonstrated by our long-term commitment towards developing a comprehensive portfolio of biosimilars.
In immunology, our pipeline includes biosimilars of adalimumab and tocilizumab. In oncology, our pipeline currently includes a biosimilar of pegfilgrastim. In the field of biosimilars, Fresenius Kabi is continuously committed to developing new medicines in these important therapeutic area; we have multiple candidates in early phase development, in both the autoimmune and oncology therapeutic areas.
To learn about Fresenius Kabi’s biosimilars and about biosimilars in general:
ERROR: UNKNOWN TRANSLATION 'loginRequiredHeadline'
ERROR: UNKNOWN TRANSLATION 'loginRequiredShortText'ERROR: UNKNOWN TRANSLATION 'loginRequiredText'